Abstract:Abstract Background Numerous laboratory and clinical studies have evidenced that MAO‐B inhibitors are a potential therapeutic approach for the treatment of AD. Thus, drugs used to inhibit activated MAO, including rasagiline, ladostigil and selegiline, may provide neuroprotection against AD by improving cognitive impairment, modulating the proteolytic cleavage of APP and decreasing levels of Aβ protein fragments that accumulate in the brain. Future clinical studies on MAO inhibitors for the treatment of AD may provide further insights into the mechanism of action of antioxidants as therapeutic agents for AD. Method Series of donepezil‐indolyl hybrids were prepared and characterized via highresolution mass spectrometry, 1 H nuclear magnetic resonance and 13 C nuclear magnetic resonance techniques. In vitro fluorometric assay (by Amplex® UltraRed reagent to detect hydrogen peroxide or peroxidase activity in biological samples or enzymes.) was used to investigate the activity of the synthesized compounds on both MAO‐A and MAO‐B isozymes as well as acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) by Ellman method with modifications. Result The biological evaluation of molecules 1‐30 showed that most of these compounds are potent, in the nanomolar range, and selective AChEI, with moderate and equipotent selectivity for MAO‐A and MAO‐B inhibition. In overall, compound 11, as a potent and selective dual AChEI, showing a moderate MAO inhibitory profile, can be considered as an attractive multipotent drug for further development on two key pharmacological targets playing key roles in the therapy of Alzheimer’s disease. Conclusion The pharmacological profile of compound 11, as well as the fact that it is a readily available compound in a short synthetic sequence, in good chemical yields, prompts us to select it as a lead‐compound for further optimization in our current research programme targeted to the preparation of new molecules for the potential treatment of AD.

Combination of NSAIDs with Donepezil As Multi-Target Directed Ligands for the Treatment of Alzheimer’s Disease

Design, Synthesis and Biological Evaluation of 2-Styryl-5-hydroxy-4-pyrone Derivatives and Analogues As Multiple Functional Agents with the Potential for the Treatment of Alzheimer's Disease.

Synthesis and evaluation of multi-target-directed ligands for the treatment of Alzheimer's disease based on the fusion of donepezil and melatonin

Searching for the Multi-Target-Directed Ligands Against Alzheimer’s Disease: Discovery of Quinoxaline-Based Hybrid Compounds with AChE, H3R and BACE 1 Inhibitory Activities

Novel Donepezil–Arylsulfonamide Hybrids as Multitarget-Directed Ligands for Potential Treatment of Alzheimer’s Disease

Development of multiple-target anti-Alzheimer′s agents

Synthesis and evaluation of donepezil–ferulic acid hybrids as multi-target-directed ligands against Alzheimer's disease

Design, synthesis and biological evaluation of novel donepezil–coumarin hybrids as multi-target agents for the treatment of Alzheimer’s disease

A Multi-Target Directed Ligands Strategy for the Treatment of Alzheimer's Disease: Dimethyl Fumarate Plus Tranilast Modified Dithiocarbate As AChE Inhibitor and Nrf2 Activator.

The Development of 2-Acetylphenol-donepezil Hybrids As Multifunctional Agents for the Treatment of Alzheimer's Disease

Design, Synthesis and Evaluation of Fused Hybrids with Acetylcholinesterase Inhibiting and Nrf2 Activating Functions for Alzheimer's Disease.

Design, synthesis, and evaluation of dual‐target inhibitors for the treatment of Alzheimer's disease

Design, Synthesis, and Evaluation of Multitarget-Directed Ligands Against Alzheimer's Disease Based on the Fusion of Donepezil and Curcumin.

Donepezil-based Multi-Functional Cholinesterase Inhibitors for Treatment of Alzheimer's Disease

Design, Synthesis, and Biological Evaluation of Dual-Target Inhibitors of Acetylcholinesterase (ache) and Phosphodiesterase 9A (PDE9A) for the Treatment of Alzheimer's Disease

Donepezil‐indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer’s disease

Novel Donepezil-Chalcone-rivastigmine Hybrids As Potential Multifunctional Anti-Alzheimer's Agents: Design, Synthesis, in Vitro Biological Evaluation, in Vivo and in Silico Studies.

Design, synthesis and biological evaluation of dual acetylcholinesterase and phosphodiesterase 5A inhibitors in treatment for Alzheimer's disease.

Multipotent Ache and Bace-1 Inhibitors for the Treatment of Alzheimer'S Disease: Design, Synthesis and Bio-Analysis of 7-Amino-1,4-dihydro-2h-isoquilin-3-one Derivates

Ache Inhibition-Based Multi-Target-Directed Ligands, A Novel Pharmacological Approach for the Symptomatic and Disease-Modifying Therapy of Alzheimer'S Disease

Design, Synthesis, and Biological Evaluation of Novel Chromanone Derivatives as Multifunctional Agents for the Treatment of Alzheimer's Disease